Whalesbook
Market Girne par bhi Dr. Reddy's ne ki 'Safety' ki taraf Dawaat!
Kal kya hua, Dr. Reddy's Laboratories ka stock 7% se zyada badh gaya, around ₹1,295.10 par pahunch gaya. Zyadatar market, jaise Sensex aur Nifty, neeche ja rahe the, lekin pharma stock ne sabko piche chhod diya. Aisa lag raha hai jaise log 'safe' cheezon mein paisa laga rahe hain, jab geopolitics aur inflation (crude oil $100 cross kar gaya) ki wajah se risk badh raha hai.
Valuation Dekho Zara!
Ek taraf jab market mein halchal thi, tab Dr. Reddy's ka valuation thoda alag dikh raha tha. Currently, iska Price-to-Earnings (P/E) ratio lagbhag 17-18x hai. Yeh medical sector ke average 30.71x se kaafi kam hai. Sun Pharmaceutical Industries jaise competitors 36.5x par trade kar rahe hain. Lekin, yeh attractive valuation bhi analyst ke concerns ke saath aata hai. Kuch log expect kar rahe hain ki next year earnings mein lagbhag 8% ki girawat ho sakti hai. Company ki market cap around $10.7 billion hai.
Pharma Sector Ki Apni Pareshaniyan
Chahe defensive appeal ho, pharma sector ko kaafi bade risks face karne pad rahe hain. West Asia mein tensions ki wajah se drugs banane ke liye zaruri raw materials ki supply chain disrupt ho rahi hai, jisse cost badh sakti hai aur availability par bhi asar pad sakta hai. India ka Active Pharmaceutical Ingredients (APIs) ke liye China par depend karna bhi ek bada risk hai. Dr. Reddy's, jo US jaise export markets mein active hai, woh bhi isse bach nahi payegi. Bade players ki baat karein toh Sun Pharma ne Q1 FY26 mein ₹13,851.40 crore ki revenue report ki thi, jabki Dr. Reddy's ki ₹8,572.10 crore thi. Cipla bhi hai, jo domestic market aur respiratory business mein strong hai, aur uska P/E 21-25x ke aas paas hai.
Analyst Aur Regulatory Hurdles
Aaj stock ke itna bhagne ka koi specific company announcement toh nahi tha, lagta hai yeh overall market sentiment ka hi kamaal hai. Par abhi bhi kaafi challenges hain. Citi ke analysts ne Dr. Reddy's ko 'sell' rating di hai, aur Morgan Stanley ne bhi FY25-26 ke liye earnings estimates kam kar diye hain. Company ko Brazil ke health regulator ANVISA se diabetes aur weight-loss drug ke liye rejection mila hai, jo market entry delay kar sakta hai. Canada mein Apotex se bhi competition hai. Yeh regulatory issues aur kam earnings expectations short-term mein stock par pressure bana sakte hain. Stock April mein short-term rising trend bhi tod chuka tha.
Aage Kya? Thoda Sabar Rakho!
Future ki baat karein toh, Dr. Reddy's ki revenue mein saalana around 5.4% ki growth ka forecast hai, lekin earnings thodi kam ho sakti hain. Analysts ka consensus price target lagbhag ₹1,314 hai, jo current levels se sirf 8% ka upside dikhata hai. Company ka US market mein strong presence aur defensive sector mein hona volatility mein stability de sakta hai, par ongoing geopolitical risks, supply chain issues aur regulatory hurdles ki wajah se cautious rehna chahiye. Yeh rally, jo defensive buying se hui hai, shayad tab tak na bane jab tak market concerns kam na ho ya company ke growth drivers mein koi naya obstacle na aaye.